First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia

BMC Pregnancy and Childbirth

Volumn 13, Issue , 2013, Pages

  Saxena, Aditi R ^a   Seely, Ellen W ^a   Rich Edwards, Janet W ^a   Wilkins Haug, Louise E ^a   Karumanchi, S Ananth ^b   McElrath, Thomas F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREGNANCY ASSOCIATED PLASMA PROTEIN A; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; LONGITUDINAL STUDY; MULTICENTER STUDY; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANT WOMAN; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; METABOLISM; NONPARAMETRIC TEST; ODDS RATIO; PREGNANCY; STATISTICAL MODEL; TIME FACTOR;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; LINEAR MODELS; ODDS RATIO; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; STATISTICS, NONPARAMETRIC; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84875690552     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-13-85     Document Type: Article

References (34)

1. Maynard SE, Karumanchi SA, Thadhani R. Hypertension and kidney disease in pregnancy. Brenner & Rector's the kidney 2008, 1567-1595. Philadelphia: Saunders Elsevier, Brenner BM, 8.
2. Leslie K, Thilaganathan B, Papageorghiou A. Early prediction and prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011, 25(3):343-354. 10.1016/j.bpobgyn.2011.01.002, 21376671.
3. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH, Fetal Medicine Foundation Second Trimester Screening Group An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 2005, 193(2):429-436. 10.1016/j.ajog.2004.12.014, 16098866, Fetal Medicine Foundation Second Trimester Screening Group.
4. McElrath TF, Lim KH, Pare E, Rich-Edwards J, Pucci D, Troisi R, Parry S. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012, 207(5):407.
5. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998, 338(14):955-961. 10.1056/NEJM199804023381404, 9521983.
6. Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000, 107(10):1265-1270. 10.1111/j.1471-0528.2000.tb11618.x, 11028579.
7. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002, 87(4):1762-1767. 10.1210/jc.87.4.1762, 11932314.
8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350(7):672-683. 10.1056/NEJMoa031884, 14764923.
9. Hagmann H, Thadhani R, Benzing T, Karumanchi SA, Stepan H. The Promise of Angiogenic Markers for the Early Diagnosis and Prediction of Preeclampsia. Clin Chem 2012, 58(5):837-845. 10.1373/clinchem.2011.169094, 22431894.
10. Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008, 111(6):1403-1409. 10.1097/AOG.0b013e3181719b7a, 18515525.
11. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010, 202(2):161.
12. Anonymous Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000, 183(1):S1-S22. 10.1067/mob.2000.107928, 10944363, Anonymous.
13. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. CPEP Study Group: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355(10):992-1005. 10.1056/NEJMoa055352, 16957146.
14. Yudkin PL, Aboualfa M, Eyre JA, Redman CW, Wilkinson AR. New birthweight and head circumference centiles for gestational ages 24 to 42 weeks. Early Hum Dev 1987, 15(1):45-52. 10.1016/0378-3782(87)90099-5, 3816638.
15. Folkersen J, Grudzinskas JG, Hindersson P, Teisner B, Westergaard JG. Pregnancy-associated plasma protein A: circulating levels during normal pregnancy. Am J Obstet Gynecol 1981, 139(8):910-914.
16. Laursen LS, Overgaard MT, Soe R, Boldt HB, Sottrup-Jensen L, Giudice LC, Conover CA, Oxvig C. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett 2001, 504(1-2):36-40.
17. Sun IY, Overgaard MT, Oxvig C, Giudice LC. Pregnancy-associated plasma protein A proteolytic activity is associated with the human placental trophoblast cell membrane. J Clin Endocrinol Metab 2002, 87(11):5235-5240. 10.1210/jc.2002-020561, 12414897.
18. Canini S, Prefumo F, Pastorino D, Crocetti L, Afflitto CG, Venturini PL, De Biasio P. Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Fertil Steril 2008, 89(1):174-178. 10.1016/j.fertnstert.2007.02.024, 17509577.
19. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111(5):649-658. 151901, 12618519.
20. Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, Connor JM, Dobbie R. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007, 109(6):1316-1324. 10.1097/01.AOG.0000265804.09161.0d, 17540803.
21. Kusanovic JP, Romero R, Jodicke C, Mazaki-Tovi S, Vaisbuch E, Erez O, Mittal P, Gotsch F, Chaiworapongsa T, Edwin SS, Pacora P, Hassan SS. Amniotic fluid soluble human leukocyte antigen-G in term and preterm parturition, and intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med 2009, 22(12):1151-1166. 10.3109/14767050903019684, 3424396, 19916713.
22. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008, 199(3):266.e1-266.e6.
23. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010, 122(5):478-487. 10.1161/CIRCULATIONAHA.109.895458, 20644016.
24. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004, 89(2):770-775. 10.1210/jc.2003-031244, 14764795.
25. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007, 50(1):137-142. 10.1161/HYPERTENSIONAHA.107.087700, 17515455.
26. Youssef A, Righetti F, Morano D, Rizzo N, Farina A. Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (> 34 weeks) pre-eclampsia. Prenat Diagn 2011, 31(12):1141-1146.
27. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32(6):732-739. 10.1002/uog.6244, 18956425.
28. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR, Conover CA. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A 1999, 96(6):3149-3153. 10.1073/pnas.96.6.3149, 15910, 10077652.
29. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, Keshet E. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008, 102(12):1566-1574. 10.1161/CIRCRESAHA.108.171504, 18515749.
30. Oxvig C, Sand O, Kristensen T, Gleich GJ, Sottrup-Jensen L. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J Biol Chem 1993, 268(17):12243-12246.
31. Oxvig C, Haaning J, Kristensen L, Wagner JM, Rubin I, Stigbrand T, Gleich GJ, Sottrup-Jensen L. Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma. J Biol Chem 1995, 270(23):13645-13651. 10.1074/jbc.270.23.13645, 7539791.
32. Ramaha A, Celerier J, Patston PA. Characterization of different high molecular weight angiotensinogen forms. Am J Hypertens 2003, 16(6):478-483. 10.1016/S0895-7061(03)00053-0, 12799097.
33. Giudice LC, Conover CA, Bale L, Faessen GH, Ilg K, Sun I, Imani B, Suen LF, Irwin JC, Christiansen M, Overgaard MT, Oxvig C. Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. J Clin Endocrinol Metab 2002, 87(5):2359-2366. 10.1210/jc.87.5.2359, 11994388.
34. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A, Kellems RE, Xia Y. Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 2007, 100(1):88-95. 10.1161/01.RES.0000254703.11154.18, 3266823, 17158338.